EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links


[Á¦2ȸ web-seminar - À§½Äµµ¿ª·ùÁúȯÀÇ Áø´Ü°ú Ä¡·á 2 - Áú¹®¿¡ ´ëÇÑ ´äº¯]

Previous | Next

»ï¼º¼­¿ïº´¿ø ÆÄÆ®³ÊÁî ¼¾ÅÍ ÁÖ°üÀ¸·Î ÁøÇàÇÏ´Â web-seminar¿¡ Âü¿©ÇØ Áּż­ °¨»çÇÕ´Ï´Ù. 4¿ù 7ÀÏ web-seminar¿¡¼­ ³ª¿Ô´ø Áú¹®¿¡ ´ëÇÑ ´äº¯À» Á¤¸®ÇÏ¿´½À´Ï´Ù.

* Position statement: ȯÀÚ¸¶´Ù »óȲÀÌ ´Ù¸¨´Ï´Ù. Á÷Á¢ ȯÀÚ¸¦ º¸Áö ¾ÊÀº »óÅ¿¡¼­ Áú¹®¿¡ ´äÇϱâ´Â ½±Áö ¾Ê½À´Ï´Ù. Àü¹®°¡¸¶´Ù »ý°¢ÀÌ ´Ù¸£°Å³ª, Çй®Àû ±Ù°Å°¡ ºÎÁ·ÇÑ °æ¿ìµµ ¸¹½À´Ï´Ù. ¿©±â Á¦½ÃÇÏ´Â ´äº¯Àº ÀúÀÇ °³ÀÎÀÇ°ßÀÔ´Ï´Ù. º´¿øÀ̳ª ÇаèÀÇ °ø½Ä ÀÔÀå°ú ´Ù¸¦ ¼ö ÀÖ½À´Ï´Ù. ÃÖÁ¾ ÆÇ´ÜÀº ¿©·¯ ¼±»ý´Ôµé²²¼­ ³ª¸§´ë·ÎÀÇ ÆÇ´Ü°ú °æÇè, ±×¸®°í Çй®Àû ±Ù°Å¿¡ µû¶óÁֽñ⠹ٶø´Ï´Ù. °¨»çÇÕ´Ï´Ù.


Q. ACE inhibitor¸¦ »ç¿ëÇÏÁö ¾Ê°í chronic sinusitis°¡ ¾ø´Â ¸¸¼º ±âħ ȯÀÚ¿¡¼­ GERD¿Í È£Èí±âÁúȯ (asthma or eosinophilic bronchitis)À» ¾î¶»°Ô °¨º°ÇϽôÂÁö¿ä?

A. ¾î·Á¿î Áú¹®ÀÔ´Ï´Ù. È£Èí±â ³»°ú¿¡¼­ È£Èí±â ÁúȯÀÇ °¡´É¼ºÀÌ ³·Àº °ÍÀ¸·Î Æò°¡µÈ ÈÄ Á¦°Ô ÀǷڵǴ °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀüÇüÀûÀÎ GERD Áõ»óÀÌ ÀÖÀ¸¸é PPI¸¦ Åõ¾àÇÏ°í ±×·¸Áö ¾ÊÀ¸¸é 24½Ã°£ pH °Ë»ç ȤÀº PPI test¸¦ ÇØ º¼ ¼ö ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù.

õ½Ä ȯÀÚ Áß ¾Æ·¡ Áõ»óÀÌ ÀÖÀ¸¸é GERD¸¦ ÀǽÉÇØ º¸½Ê½Ã¿À.
1) ¼ºÀο¡¼­ ½ÃÀÛµÈ Ãµ½Ä
2) õ½ÄÀÇ °¡Á··ÂÀÌ ¾ø´Â °æ¿ì
3) õ½ÄÀÌ ÀÖ±â Àü¿¡ ¿ª·ù Áõ»óÀÌ ¼±ÇàµÈ °æ¿ì
4) ½ÄÈÄ¿¡ wheezingÀÌ ½ÉÇØÁú ¶§
5) ¾ß°£¿¡ ±âħÀ̳ª wheezingÀÌ ÀÖÀ» ¶§
6) ThophyllineÀ̳ª beta-2 Â÷´ÜÁ¦¿¡ ÀÇÇؼ­ ¾ÇÈ­µÇ´Â õ½Ä


Q. Refractory GERD¿¡¼­ ¾î¶² °æ¿ì achalasia¸¦ ÀǽÉÇϽôÂÁö¿ä?

A. Dysphagia Áõ»ó¿©ºÎ°¡ °¡Àå Áß¿äÇÕ´Ï´Ù. ¹°·Ð GERD¿¡¼­µµ ½Ä»ç ÃʱâÀÇ °¡º­¿î dysphagia´Â °¡´ÉÇÕ´Ï´Ù. ³»½Ã°æ ¼Ò°ßµµ Áß¿äÇÕ´Ï´Ù. Mucosal break°¡ ¾ø°í, hiatal herniaµµ ¾ø°í, LES toneÀÌ Á¤»ó ȤÀº ´Ù¼Ò ³ô¾Æº¸ÀÌ´Â °æ¿ì¿¡ ÀǽÉÇÒ ¼ö ÀÖ½À´Ï´Ù. ºñ±³Àû ÀþÀº ³ªÀÌ¿¡ ¹ß»ýÇÑ refractory GERD¿¡¼­µµ ÇѹøÂëachalasia¸¦ ÀǽÉÇØ º¸¾Æ¾ß ÇÕ´Ï´Ù. Barium esophagography¸¦ ±ÇÇÕ´Ï´Ù.


Q. GERDÀÇ ºñÀüÇüÀûÀÎ Áõ»óÀ¸·Î ¾î±ú³ª °¡½¿ºÎÀ§ ±ÙÀ°ÅëÁõµµ °¡´ÉÇմϱî? PPI Åõ¿© ÈÄ È£ÀüµÇ¾ú´Ù´Â ȯÀÚ°¡ Àִµ¥¿ä.

A. ±Ý½ÃÃʹ®ÀÔ´Ï´Ù. ¾Æ¸¶ ¾Æ´Ò °Í °°½À´Ï´Ù. ÀúÀý·Î ÁÁ¾ÆÁø °ÍÀ̶ó°í ÃßÁ¤ÇÕ´Ï´Ù. PPI¿Í ¹«°üÇÏ°Ô.


Q. PPI´Â ½ÄÈÄ¿¡µµ º¹¿ëÇÒ ¼ö ÀÖ½À´Ï±î? Ãëħ Àü¿¡ º¹¿ëÇϸé È¿°ú´Â ÀÖ½À´Ï±î? ÃÖ±Ù ¹Ý°¨±â°¡ ±ä PPI (dexlansoprazole)°¡ ¹ß¸ÅµÇ¾ú´Âµ¥ À¯¿ë¼ºÀÌ ÀÖ½À´Ï±î?

A. ¸Å¿ì Áß¿äÇÑ Áú¹®ÀÔ´Ï´Ù. ±×·±µ¥ ´äÀº ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù. °ú°Å¿¡´Â ½ÄÀü¿¡ ¸Ô´Â °ÍÀ» Áß¿ä½Ã Çߴµ¥ ÃÖ±Ù¿¡´Â ±×·¸Áö ¾Ê´Ù´Â ÁÖÀåµµ Àֱ⠶§¹®ÀÔ´Ï´Ù.

2015³â 4¿ù 10ÀÏ ÇÑ Á¦¾àȸ»ç PM¿¡°Ô ÇÑ Áú¹®À» º¸³Â°í ¸çÄ¥ ÈÄ ¹ÞÀº ´äº¯À» ¼Ò°³ÇÕ´Ï´Ù.

Q. (ÀÌÁØÇà) PPI´Â ½ÄÀü¿¡ ¸Ô´Â ¾àÀÔ´Ï´Ù. ±×·±µ¥ ½ÄÈÄ¿¡ NexiumÀ» ¸ÔÀ¸¸é ¾î´À Á¤µµ Èí¼öµÇ´ÂÁö ÀڷḦ °¡Áö°í ÀÖÀ¸¸é ºÎŹµå¸³´Ï´Ù.

A. (ȸ»ç PM) Áö±Ý±îÁö ÁøÇàµÈ ¿¬±¸¿¡ ÀÇÇϸé, ½ÄÈÄ º¹¿ë ½Ã Èí¼öÀ²ÀÌ ¾à°£ ÀúÇصDZä ÇÏÁö¸¸, intragastric pH control¿¡´Â º¯È­°¡ ¾ø´Ù°í µÇ¾î ÀÖ½À´Ï´Ù. 2014³â¿¡ updateµÈ Nexium monograph¿¡´Â ¾Æ·¡¿Í °°ÀÌ Ç¥½ÃµÇ¾î ÀÖ½À´Ï´Ù.

Drug-Food Interactions: Food intake delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.

°ü·Ã ³í¹®: The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH (Junghard. Eur J Clin Pharmacol. 2002)"

ȸ»ç¿¡¼­ Á¦½ÃÇÑ ÀÚ·á (Eur J Clin Pharmacol. 2002)ÀÇ °á·ÐÀº ´ÙÀ½°ú °°¾Ò½À´Ï´Ù. "The reduced AUC after food intake is compensated by a prolonged time period with quantifiable plasma concentrations, which explains the lack of influence of food intake on %pH>4." Áï ½ÄÈÄ¿¡ esomeprazoleÀ» ¸ÔÀ¸¸é peak plasma concentrationÀÌ ´Ê°Ô ³ªÅ¸³ª°í AUC (area under curve) °ªµµ ³·Áö¸¸ quantifiable plasma concentrationÀÇ Áö¼Ó½Ã°£ÀÌ ±æ¾îÁö¸é¼­ pH 4 ÀÌ»óÀÎ ½Ã°£Àº Â÷ÀÌ°¡ ¾ø´Ù´Â ¼³¸íÀÔ´Ï´Ù. Áï ½ÄÈÄ¿¡ ¸Ô¾îµµ º° »ó°üÀÌ ¾ø´Ù´Â Àǹ̷ΠÇؼ®µË´Ï´Ù.


Day 1°ú day 5 ¸ðµÎ ½ÄÈÄ¿¡ peak°¡ ³·¾ÆÁö°í AUC°¡ ÀÛ¾ÆÁý´Ï´Ù.


ÆĶõ»ö ÁÙ ºÎÀ§¸¦ ÁÖ¸ñÇϽʽÿä. pH 4 ÀÌ»ó ½Ã°£Àº Â÷ÀÌ°¡ ¾ø½À´Ï´Ù.

Refractory GERD¿¡ ´ëÇÑ °­ÀÇ¿¡¼­´Â Ç×»ó °øº¹¿¡ ¾àÀ» ¸ÔÁö ¾Ê´Â ȯÀÚ À̾߱Ⱑ ³ª¿É´Ï´Ù. °øº¹¿¡ PPI¸¦ ¸ÔÁö ¾Ê°í ¿©´À ¾àó·³ ½ÄÈÄ¿¡ ¾àÀ» ¸Ô´Â »ç¶÷ÀÌ Àý¹Ý±îÁö µÈ´Ù´Â ÀÚ·áµµ ÀÖ½À´Ï´Ù. ±×·±µ¥ PPIÀÇ º¹¾à ½Ã°£ÀÌ Áß¿äÇÏ´Ù´Â ÁÖÀåÀÇ ±Ù°Å´Â ¾àÇÕ´Ï´Ù. ¸î °¡Áö ÀÌÀ¯°¡ ÀÖ½À´Ï´Ù. (1) ½ÄÈÄ¿¡ PPI¸¦ ¸Ô¾ú´Ù´Â ÀÌÀ¯·Î refractory GERD·Î °£ÁÖµÈ È¯ÀÚ¿¡¼­ PPI º¹¾à½Ã°£À» ½ÄÀüÀ¸·Î ¹Ù²Û ÈÄ Áõ»ó º¯È­¸¦ ºÐ¼®ÇÑ ÁÁÀº ¿¬±¸¸¦ º» ±â¾ïÀÌ ¾ø½À´Ï´Ù. ¿¬±¸¸¦ ÇÏÁö ¾Ê¾Ò´ø °ÍÀϱî¿ä? ¾Æ´Ï¸é negative study¿©¼­ ÃâÆÇÀÌ µÇÁö ¾ÊÀº °ÍÀϱî¿ä? (2) °³ÀÎÀûÀ¸·Î´Â º¹¾à½Ã°£À» ½ÄÈÄ¿¡¼­ ½ÄÀüÀ¸·Î ¹Ù²Û ÈÄ Áõ»óÀÌ ÇöÀúÇÏ°Ô ÁÁ¾ÆÁø ȯÀÚ¸¦ °æÇèÇÑ ÀûÀÌ ¾ø½À´Ï´Ù. ±â²¯ÇØ¾ß ¾Ö¸ÅÇÑ Á¤µµ¿´½À´Ï´Ù. (3) À§¿¡ ¼Ò°³ÇÑ ÀÚ·á (Eur J Clin Pharmacol. 2002)ó·³ PPI º¹¾à ½Ã°£¿¡ µû¸¥ À§³» pH Â÷ÀÌ°¡ ¾ø´Ù¸é Áõ»ó°³¼± È¿°úµµ Â÷ÀÌ°¡ ¾øÀ» ¼ö ÀÖ½À´Ï´Ù.

Àú´Â PPI¸¦ °øº¹¿¡ ¸Ô´Â °ÍÀÌ Á¤¸»·Î Áß¿äÇÑÁö ¾à°£ÀÇ Àǹ®À» °¡Áö°í ÀÖ½À´Ï´Ù. ´Ù¸¸ ¾àÀü¿¡ ½ÄÀü¿¡ ¸Ôµµ·Ï µÇ¾î ÀÖ°í, Àü¹®°¡µéµµ ´ë°­ ½ÄÀüÀ» ±ÇÇÏ°í ÀÖÀ¸¹Ç·Î ȯÀÚ¿¡°Ô ½ÄÀü¿¡ µå½Ãµµ·Ï ó¹æÇÏ°í ÀÖÀ» »ÓÀÔ´Ï´Ù. °£È¤ ½ÄÈÄ¿¡ ¸ÔÀ¸¸é ¾î¶»°Ô µÇ´Â°¡ ¹°¾î¿À´Â ȯÀÚ°¡ ÀÖ½À´Ï´Ù. "°¡´ÉÇÏ¸é ½ÄÀü¿¡ µå½Ã°í ¸¸¾à ½ÄÈÄ¿¡ µå¼Åµµ Áõ»óÀÌ Àß Á¶ÀýµÇ¸é ±×´ë·Î Çϼŵµ ÁÁÀ» °Í °°½À´Ï´Ù."¶ó°í ´äÇÏ°í ÀÖ½À´Ï´Ù. Áõ»ó¸¸ ÁÁ¾ÆÁö¸é ±×¸¸À̴ϱî¿ä.

°ü·ÃµÈ À̽´°¡ ÀÖ½À´Ï´Ù. Helicobacter Á¦±ÕÄ¡·á ¶§ PPI¸¦ °øº¹¿¡ Åõ¾àÇØ¾ß ÇÏ´ÂÁö, ¾Æ´Ï¸é ´Ù¸¥ ¾à°ú ÇÔ²² ½ÄÈÄ¿¡ Åõ¾àÇصµ ÁÁÀºÁö¿¡ ´ëÇÑ ±Ã±ÝÁõÀÔ´Ï´Ù. ÀÏÀü¿¡ helicobacter.html (Áú¹® 7)¿¡¼­ »ó¼¼È÷ ³íÇÑ ¹Ù ÀÖµíÀÌ ½ÄÈÄ¿¡ ´Ù¸¥ Ç×»ýÁ¦¿Í ÇÔ²² º¹¿ëÇصµ ¹«¹æÇÏ´Ù´Â °ÍÀÌ ÀϹÝÀûÀÎ ÀÇ°ßÀÔ´Ï´Ù.

ÃÖ±Ù ¹ß¸ÅµÈ dexlansoprazoleÀº ÇÑ capsule¿¡ µÎ °¡Áö ´Ù¸¥ ÇüÅÂÀÇ granuleÀÌ À־ Ç÷Áß³óµµ°¡ dual peak¸¦ º¸ÀÌ°í plasma half-life°¡ ±æ´Ù´Â Á¡ÀÌ marketing pointÀÎ °Í °°½À´Ï´Ù. ±×·±µ¥ plasma half-life°¡ ±æ´Ù°í ¾àÈ¿°¡ ÁÁÀ»Áö´Â Àß ¸ð¸£°Ú½À´Ï´Ù. °³ÀÎÀûÀÎ ÀÓ»ó °æÇèÀÌ °ÅÀÇ ¾ø¾î¼­ º¸´Ù ÀÚ¼¼ÇÑ ´äº¯Àº µå¸± ¼ö ¾ø´Â »óÅÂÀÔ´Ï´Ù.


»¡¸® Èí¼öµÇ´Â Åä³¢¿Í õõÈ÷ Èí¼öµÇ´Â °ÅºÏÀ̶ó´Â ¼³Á¤ÀÌ Àç¹ÌÀÖ½À´Ï´Ù.


Dual peak¸¦ º¸ÀÌ°í detectable plasma concentrationÀ» º¸ÀÌ´Â ½Ã°£ÀÌ ±æ´Ù´Â °ÍÀº »ç½ÇÀÎ °Í °°½À´Ï´Ù.


Q. PPI¸¦ ¸Ô´Â ȯÀÚµéÀÌ ¾àÀ» ²÷À¸¸é 2-3ÀÏ ³»¿¡ ´Ù½Ã Áõ»óÀÌ »ý±ä´Ù°í ÇÕ´Ï´Ù. PPI¸¦ Áß´ÜÇϱâ À§ÇØ ¾î¶² ¹æ¹ýÀ» »ç¿ëÇÏÁö´ÂÁö ±Ã±ÝÇÕ´Ï´Ù.

A. GERD´Â Ä¡·áÇÏ´Â º´À̶ó±âº¸´Ù´Â °ü¸®ÇÏ´Â º´ÀÔ´Ï´Ù. PPI¿¡ ¹ÝÀÀÀÌ ÁÁÀº ȯÀÚ¶óµµ ¾àÀ» ²÷À¸¸é À̳» Áõ»óÀÌ ¹ß»ýÇϱ⠶§¹®ÀÔ´Ï´Ù. ºñ¾à¹°¿ä¹ýÀÇ È¿°ú´Â Á¦ÇÑÀûÀÔ´Ï´Ù. On demand therapy¸¦ Çϴ ȯÀÚµéÀÇ °æ¿ì¸¦ º¸´õ¶óµµ PPI¸¦ ²÷À¸¸é À̳» Áõ»óÀÌ ¹ß»ýÇϱ⠶§¹®¿¡ ÀÏÁÖÀÏ¿¡ Æò±Õ 2¹ø Á¤µµ PPI¸¦ µå½Ã°Ô µË´Ï´Ù.

GERD ȯÀÚ°¡ ºñ¾à¹°¿ä¹ýÀ» ÅëÇÏ¿© PPI¸¦ ²÷°Ô µÇ¸é ÁÁ°ÚÁö¸¸ ±×·² °æ¿ì´Â ¸¹Áö ¾Ê½À´Ï´Ù. Áõ»óÀÌ ¾øÀ¸¸é¼­ ¾àÀ» ÃÖ¼ÒÇÑÀ¸·Î ¾²µµ·Ï PPI Åõ¾à Àü·«À» Àß Àâ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. ÀÌ·± °üÁ¡¿¡¼­ Àú´Â every other day·Î Åõ¾àÇÏ´Â °ÍÀ» ÁÁ¾ÆÇÕ´Ï´Ù. Threshold therapy¶ó°í ÇÕ´Ï´Ù. Threshold therapy´Â ¾Æ·¡¿Í °°ÀÌ ÇÏ´Â °ÍÀÔ´Ï´Ù (Zancy. Aliment Pharmacol Ther 2005;21:1299-312).

i) For 'threshold' therapy, patients gradually increase the interval between medications (for example, to every second or third day) as long as symptoms do not recur.

ii) The patient titrates the medication down to a frequency that still maintains adequate control of symptoms.

iii)This is different from on-demand therapy where each time the patient waits for recurrence of symptoms.


Q. Standard dose¿Í half dose¸¦ µÎ ¹ø ÁÖ´Â °ÍÀÇ È¿°ú´Â ¸¹ÀÌ ´Ù¸¥Áö ±Ã±ÝÇÕ´Ï´Ù.

A. ¾à¸®ÇÐÀûÀ¸·Î peak°¡ Áß¿äÇÑ ¾àÀº ¸¹Àº ¾çÀ» ÇѲ¨¹ø¿¡ Åõ¾àÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ´ëºÎºÐÀÇ Ç×»ýÁ¦°¡ ±×·¸½À´Ï´Ù. CephalosporinÀ» ÇÏ·ç Çѹø IV·Î Åõ¿©ÇÏ´Â °ÍÀº ÀÌ ¶§¹®ÀÔ´Ï´Ù.

¾à¸®ÇÐÀûÀ¸·Î AUC (area under curve)°¡ Áß¿äÇÑ ¾àÀº ¿©·¯¹ø ³ª´² ÁÖ´Â °ÍÀÌ ÁÁÀ» ¼ö ÀÖ½À´Ï´Ù. ¹°·Ð ¾àÀ» ¿©·¯¹ø ¸Ô´Â ºÒÆí°¨°ú ¾à¸®ÇÐÀû À̵æÀÇ ±ÕÇüÀ» °í·ÁÇØ¾ß ÇÕ´Ï´Ù. PPI´Â AUC°¡ Áß¿äÇÑ ¾àÀÌÁö¸¸, ÇÏ·ç Çѹø º¹¿ëÇصµ 24½Ã°£ ÀÌ»ó ¾àÈ¿°¡ Áö¼ÓµË´Ï´Ù. µû¶ó¼­ ÇÏ·ç Çѹø Åõ¾àÀÌ Ç¥ÁØÀÔ´Ï´Ù. Half dose¸¦ ÇÏ·ç µÎ¹ø º¹¿ëÇϸé À§»ê¾ïÁ¦È¿°ú´Â Á¶±Ý ´õ ÁÁ°ÚÁö¸¸ ¹«Ã´ ºÒÆíÇÒ °ÍÀÔ´Ï´Ù. °Ô´Ù°¡ half dose PPI¸¦ ÇÏ·ç µÎ¹øÀ¸·Î ó¹æÇÏ´Â °ÍÀº Çã¿ëµÇÁö ¾Ê°í ÀÖ½À´Ï´Ù. ºÒ¹ýÀÔ´Ï´Ù. ÇÏ°í ½Í¾îµµ ÇÒ ¼ö ¾ø½À´Ï´Ù.


Q. GERD Ä¡·á ¾Ë°í¸®µë¿¡ PPI twice daily ºÎºÐÀÌ ÀÖ½À´Ï´Ù. PPI twice dailyÇÏ°í PPI¸¦ AM time¿¡ ÇÑ ¹ø ¾²°í Bed time¿¡ H2RA¸¦ ÁÖ´Â °Í Áß ¾î´À °ÍÀÌ ´õ ÁÁÀ»±î¿ä?

A. À§»êºÐºñ¸¦ ¾ïÁ¦ÇÑ´Ù´Â Ãø¸é¿¡¼­´Â PPI twice daily°¡ '¾Æħ PPI + bed time H2RA'º¸´Ù ¿ì¼öÇÒ °ÍÀÔ´Ï´Ù. Áõ»ó °³¼±À» ¾ïÁ¦ÇÒ ÃÖ¼ÒÇÑÀÇ ¾àÁ¦¸¸ ¾´´Ù´Â ÀÌÀ¯¿¡¼­ '¾Æħ PPI + bed time H2RA'¸¦ ½á º¸°í ¹ÝÀÀÀÌ ÃæºÐÄ¡ ¾ÊÀ¸¸é PPI twice daily·Î ¿Ã¸°´Ù´Â Àü·«À» »ý°¢ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·±µ¥ ¿ì¸®³ª¶ó¿¡¼­´Â PPI twice daily ó¹æÀÌ ºÒ°¡´ÉÇÑ »óȲÀÎÁö¶ó '¾Æħ PPI + bed time H2RA' ó¹æÀÌ Á¾Á¾ ÀÌ¿ëµÇ°í ÀÖ½À´Ï´Ù.


Q. Ä¡·á ¾Ë°í¸®µë¿¡ baclofenÀÌ Àִµ¥ ÀÌ ¾àÀº ±ÙÀÌ¿ÏÁ¦·Î ¾Ë°í Àִµ¥ ÀÌ°ÍÀ» »ç¿ëÇÑ °æÇèÀÌ ÀÖÀ¸½ÅÁö ±Ã±ÝÇÕ´Ï´Ù. ȯÀý±â °Ç°­ Á¶½ÉÇÏ½Ã°í ¾È³çÈ÷ °è½Ê½Ã¿ä.

A. GERDÀÇ ¹ß»ý ±âÀü¿¡ transient LES relaxationÀ̶ó´Â °ÍÀÌ ÀÖ½À´Ï´Ù. À̸¦ ¾ïÁ¦ÇÏ´Â ¾àÀÌ baclofenÀÔ´Ï´Ù. ºÎÀÛ¿ëÀÌ ¸¹°í È¿°ú´Â º°·ÎÀÎÁö¶ó °ÅÀÇ »ç¿ëµÇ´Â ¿¹°¡ ¾ø´Â °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. Àú´Â Çѹøµµ ½á º» ÀûÀÌ ¾ø½À´Ï´Ù. ³í¹® ¸î°³¸¦ º¸¾ÒÁö¸¸ È¿°ú¿¡ ´ëÇÑ È®½ÅÀÌ »ý±âÁö ¾Ê¾Ò½À´Ï´Ù.


Q. ÀüÇüÀûÀÎ GERD ȯÀÚ¿¡¼­ standard dose PPI »ç¿ë¿¡µµ È¿°ú°¡ ¾ø´Â °æ¿ì Ãß°¡ÇÒ ¼ö ÀÖ´Â ¾àÁ¦³ª ÁÖ·Î ¾²´Â ¾àÀÌ ÀÖ´ÂÁö¿ä?

A. Àú´Â refractory GERD¿¡¼­´Â ¿ì¼± Áø´ÜÀÌ Æ²¸®Áö ¾Ê¾Ò´ÂÁö ÀǽÉÇغ¾´Ï´Ù. Áø´Ü¿¡ ¹®Á¦°¡ ¾ø´Ù¸é (1) ´Ù¸¥ Á¾·ùÀÇ PPI·Î ¹Ù²ãº¾´Ï´Ù. (2) ÀϽÃÀûÀ¸·Î PPI¸¦ ÇÏ·ç µÎ¹ø µå½Ãµµ·Ï ±ÇÇغ¾´Ï´Ù. (3) diazepamÀ» ¼Ò·® Ãß°¡ÇÕ´Ï´Ù. Prokinetics´Â °ÅÀÇ ¾²Áö ¾Ê°í ÀÖ½À´Ï´Ù.


Q. ¿ª·ù¼º ½Äµµ¿° ȯÀÚ Áß ´õºÎ·èÇÔ, ½Å¹°, ¾ðÄ£ ´À³¦, ÀÛ¿­°¨À» ºñ·ÔÇÑ ÅëÁõ µîÀÌ ÀüÇô ¾øÀÌ ¸ñÀÇ À̹°°¨ µî Èĵο° Áõ»óÀ¸·Î¸¸ ¿À´Â °æ¿ì°¡ ¸î %³ª µÇ´Â°¡¿ä? ¿ä»õ ¸ñÀÇ À̹°°¨¿¡ ¿ª·ù¼º ½Äµµ¿° Áø´ÜÀÌ ¾à°£ ³²¹ßµÇ´Â °Í °°Àº ´À³¦µµ À־ Áú¹®µå¸³´Ï´Ù.

A. ¸Å¿ì ÁÁÀº Áú¹®ÀÔ´Ï´Ù. ¾à°£ÀÌ ¾Æ´Õ´Ï´Ù. ¾öû ¸¹ÀÌ ³²¹ßµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇÑ ºÒÇÊ¿äÇÑ Åõ¾àµµ ÀÌ·ç ¸»ÇÒ ¼ö ¾ø½À´Ï´Ù. ¸ñÀÇ À̹°°¨ ´Üµ¶ Áõ»óÀ¸·Î ³ª¿À´Â GERD´Â ¸Å¿ì µå¹® °Í °°½À´Ï´Ù. Ȥ½Ã 24½Ã°£ pH °Ë»ç¿¡¼­ ºñÁ¤»ó °á°ú°¡ ³ª¿À´õ¶óµµ PPI¿¡ ¹ÝÀÀÀÌ ÀÖÀ» È®·üÀº ³·À» °Í °°½À´Ï´Ù.

ÀüÇüÀûÀÎ Áõ»óÀÌ ¾ø´Â ¸ñÀÇ À̹°°¨Àº PPI·Î Á¶ÀýµÇÁö ¾Ê´Â °Í °°½À´Ï´Ù. ±â²¯ÇØ¾ß placebo È¿°úÀÏ °ÍÀÔ´Ï´Ù. °í¿ë·®À» Àå±â°£ »ç¿ëÇÏ¸é µµ¿òÀÌ µÈ´Ù´Â °ú°ÅÀÇ ¿¬±¸µéÀº º°·Î ½Å·ÚÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.


Q. ºñÀüÇüÀûÀÎ À§½Äµµ¿ª·ùÁúȯ Áõ»ó, ƯÈ÷ ¸ñÀÇ À̹°°¨Àº PPI¸¦ ½áµµ È¿°ú°¡ È®½ÇÇÏÁö ¾ÊÀº °æ¿ì°¡ ¸¹½À´Ï´Ù. ÀÌ·± °æ¿ì ±³¼ö´Ô²²¼­´Â PPI ¿ë·®°ú »ç¿ë±â°£À» ¾î¶»°Ô ó¹æÇÏ´ÂÁö ±Ã±ÝÇÕ´Ï´Ù.

A. ¾Õ¼­ ¸»¾¸µå·È½À´Ï´Ù¸¸...... ÀüÇüÀûÀÎ Áõ»óÀÌ ¾ø´Â ¸ñÀÇ À̹°°¨Àº PPI·Î Á¶ÀýµÇÁö ¾Ê´Â °Í °°½À´Ï´Ù. ±â²¯ÇØ¾ß placebo È¿°úÀÏ °ÍÀÔ´Ï´Ù. °í¿ë·®À» Àå±â°£ »ç¿ëÇÏ¸é µµ¿òÀÌ µÈ´Ù´Â °ú°ÅÀÇ ¿¬±¸µéÀº º°·Î ½Å·ÚÇÏÁö ¾Ê°í ÀÖ½À´Ï´Ù.


Q. ClopidogrelÀÇ GI event¸¦ °¨¼Ò½ÃÅ°´Â ¸ñÀûÀ¸·Î PPI¸¦ »ç¿ëÇÒ ¶§ standard dose¿Í half dose °£ÀÇ Â÷ÀÌ°¡ ÀÖ´ÂÁö¿ä?

A. ¾ö¹ÐÇÑ ºñ±³ÀÓ»óÀº ¾ø´Â °Í °°½À´Ï´Ù. Àú´Â º¸Åë half dose¸¦ ¾²°í ÀÖ½À´Ï´Ù.


Q. WarfarinÀ» ¾²°í Àִ ȯÀÚ¿¡¼­ PPI Á¾·ù¿¡ µû¶ó¼­ ÀÓ»óÀûÀÎ Àǹ̳ª ÁÖÀÇÇÒ Á¡ÀÌ ÀÖ½À´Ï±î?

A. PPI°¡ ²À ÇÊ¿äÇϸé Åõ¿©ÇØ¾ß ÇÏ°ÚÁö¸¸, °£È¤ prothrombin timeÀ» ÃøÁ¤ÇØ¾ß ÇÕ´Ï´Ù. ¾Æ·¡ Ç¥¿¡ ÀÇ°ÅÇÏ¿© Àú´Â ÁÖ·Î pantoprazoleÀ» ¼±ÅÃÇÏ°í ÀÖ½À´Ï´Ù.



Q. PPI¿Í öºÐÁ¦¸¦ °°ÀÌ Åõ¿©ÇÒ ¶§ ±³¼ö´ÔÀº ¾î¶»°Ô ó¹æÇϽʴϱî?

A. PPI¸¦ Àå±â »ç¿ëÇϸé öºÐ Èí¼ö°¡ ÀúÇصȴٴ ÀϺΠ¿¬±¸°¡ ÀÖÀ¸³ª ±×´ÙÁö ½Å·ÚÇϱâ´Â ¾î·Æ½À´Ï´Ù (¸µÅ©). À½½Ä¹°ÀÇ Fe3+°¡ Èí¼öµÇ±â À§Çؼ­´Â Fe 2+·Î ¹Ù²î¾î¾ß Çϴµ¥ ÀÌ °úÁ¤¿¡¼­ À§»êÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª öºÐ¾àÀÇ Fe 2+¼ººÐÀº ±×´ë·Î Èí¼öµÉ ¼ö À־ PPI·ÎºÎÅÍÀÇ ¿µÇâÀº ÀûÀ» °Í °°½À´Ï´Ù. Àú´Â öºÐ¾à°ú PPIÀÇ »óÈ£ÀÛ¿ëÀº º°·Î °í·ÁÇÏÁö ¾Ê°í ±×³É ó¹æÇÏ°í ÀÖ½À´Ï´Ù.

Nonheme iron (ferric, Fe3+) constitutes the majority of dietary iron consumed. To be absorbed by duodenal enterocytes, this iron subsequently must undergo a reduction into the ferrous state (Fe 2+), mediated by hydrochloric acid released from the stomach. In vivo data have shown that this absorption is related directly to the release of ferric iron by gastric juice. There also is evidence suggesting that this process is related more specifically to the vitamin C released in gastric secretions, which acts as a reducing agent and prevents the formation of insoluble compounds. Although there is concern regarding evidence that PPIs may reduce the bioavailability of ingested vitamin C, long-term follow-up evaluation of patients taking chronic daily PPIs for up to 7 years has not shown iron absorption to be clinically apparent. Further, most cases of iron malabsorption can be managed clinically with the use of medicinal iron supplements that are absorbed independent of gastric acid and vitamin C. (Medscape ¸µÅ©)


Q. Acid pocketÀº À§ÀÇ À§Ä¡ ¶§¹®¿¡, À½½Ä¹°ÀÌ GE junction±îÁö Â÷Áö ¾Ê±â ¶§¹®¿¡ Çü¼ºµÇ´Â °ÍÀΰ¡¿ä?

A. Acid pocketÀÌ »ý±â´Â ±âÀüÀº ¸íÈ®ÇÏÁö ¾Ê½À´Ï´Ù. ½ÄÀÌ ÈÄ fundus°¡ À̿ϵǰí À§¿¡¼­ À½½ÄÀÌ ¼¯ÀÌ´Â º¹ÀâÇÑ °úÁ¤ÀÇ °á°úÀÏ °ÍÀÔ´Ï´Ù.

GlasgowÀÇ Fletcher¿Í McColl µîÀº pH probe pull-through techniqueÀ» ÀÌ¿ëÇÏ¿© ½ÄÈÄ À§ÀÇ Àü¹ÝÀûÀÎ pH°¡ 4.7±îÁö ³ô¾ÆÁöÁö¸¸, À§½ÄµµÁ¢ÇպΠÁ÷ÇϺο¡ ¾à 2 cm Á¤µµ´Â pH°¡ 1.6Á¤µµ·Î ³·°Ô À¯ÁöµÇ´Â ºÎÀ§°¡ ÀÖ´Ù°í º¸°íÇϸ鼭 À̸¦ acid pocketÀ¸·Î ¸í¸íÇÏ¿´½À´Ï´Ù. ÀÌÈÄ °°Àº ¿¬±¸ÀÚµéÀº high resoluation pH-meter¸¦ ÀÌ¿ëÇÏ¿© acid pocketÀÌ ½ÄÈÄ 14ºÐ ºÎÅÍ °üÂûµÇ±â ½ÃÀÛÇÏ¿© ¾à 90ºÐ Á¤µµ Áö¼ÓµÊÀ» º¸¿©ÁÖ¾ú½À´Ï´Ù. ½ÄÈÄ À§½ÄµµÁ¢ÇպΠÁ÷ÇϺο¡ pH°¡ ³·Àº ¾×ü°¡ ¸ð¿©Àֱ⠶§¹®¿¡ TLESRÀº »ê¿ª·ù¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Â °ÍÀÔ´Ï´Ù.


Q. ÇöÀçÀÇ º¸Çè ±ÔÁ¤¿¡ µû¸£¸é ÃÖÃÊ ¿ª·ù¼º ½Äµµ¿° Áø´Ü ÈÄ PPI Àå±â ó¹æÀÌ ¾ó¸¶³ª °¡´ÉÇÏ°í Ãß°¡ ³»½Ã°æ °Ë»ç´Â ¾ðÁ¦ ÇØ¾ß Çմϱî?

A. °ü·Ã ±ÔÁ¤À» Á¤È®È÷ ¾ËÁö ¸øÇÕ´Ï´Ù. Á˼ÛÇÕ´Ï´Ù. ´Ù¸¸ Áõ»óÀÌ ÀÖ´Â °æ¿ì Áö¼ÓÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ´Â °ÍÀ¸·Î ¾Ð´Ï´Ù. Àǹ«±â·ÏÀ» Á¤È®È÷ ³²°ÜµÎ´Â °ÍÀÌ ÁÁÀ» °Í °°½À´Ï´Ù.


Q. GERD Áú¹®Àº ¾Æ´Õ´Ï´Ù¸¸, esophageal diverticulum with food stasis ȯÀÚ¿¡¼­ ±¸Ãë/½ÉÇÑ Æ®¸² ³¿»õ µîÀÇ Áõ»ó °³¼±À» À§ÇØ µµ¿òµÉ ¾àÀÌ ÀÖÀ»Áö¿ä?

A. ¾ø½À´Ï´Ù. Áõ»óÀ» µ¿¹ÝÇÑ ½Äµµ°Ô½ÇÀº endoscopic diverticular septal dissection ȤÀº surgical diverticulectomy µîÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¾à¹°Ä¡·áÀÇ ´ë»óÀº ¾Æ´Ï°í ³»½Ã°æÀû ȤÀº ¿Ü°úÀû Ä¡·á´ë»óÀ̶ó´Â ÀǹÌÀÔ´Ï´Ù. zenker.htmlÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù.


º¸¿©µå¸° Áõ·Ê Áß total gastrectomy ÈÄ ºü¸¥ ½Ã°£¿¡ vitamin B12 deficiency¸¦ º¸ÀΠȯÀÚ°¡ ÀÖ¾ú½À´Ï´Ù. ÀÌ Áõ·Ê¿¡ ´ëÇÏ¿© ±èÁø¿ë ¼±»ý´Ô²²¼­ ¾Æ·¡¿Í °°Àº comment¸¦ º¸³»Áּ̽À´Ï´Ù. °¨»çÇÕ´Ï´Ù.

"Àá½Ã ã¾Æº¸´Ï total gastrectomy ÈÄ vitamin B12 deficiency ±îÁöÀÇ median timeÀº 15°³¿ù·Î µÇ¾î ÀÖ½À´Ï´Ù. 4³â ÈÄ¿¡´Â total gastrectomyÀÇ 100%, distal gastrectomyÀÇ 16%¿¡¼­ vitamin B12 deficiency°¡ »ý±ä´Ù°í ÇÕ´Ï´Ù."



© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.